Medical cannabis linked to better sleep and wellbeing in autism
UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.
AI Summary
This observational case series followed 130 autistic adults in the UK Medical Cannabis Registry who were prescribed cannabis-based medicinal products (CBMPs). Over 18 months, participants reported improvements in anxiety and sleep quality, with both measures showing statistically significant changes from baseline (p < 0.001). Overall health-related quality of life also improved, with EQ-5D-5L scores rising from 0.43 ± 0.30 at baseline to 0.51 ± 0.32 at 18 months (p < 0.001).
The findings suggest CBMP treatment was associated with better reported wellbeing, anxiety, and sleep in these autistic adults. However, because the study had no control group, it cannot show that cannabis caused the improvements; changes could also reflect other factors, including natural fluctuations or concurrent care. Adverse events were reported by 25 participants (19.23%), and most were described as mild or moderate. The authors call for randomized controlled trials to clarify the long-term benefits and risks of CBMPs for autism spectrum disorder.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Anxiety research papers you might find interesting.
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Language models can extract documented cannabis use, but need validation
TBI study links cannabis use with symptoms, not proven effects
Explore More Research
Stay informed about the latest cannabis science.